Skip to content
Screener

EBIT at other companies

Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
$1.25B+8.3%
AbbVie logo
AbbVieABBV
$6.43B+31.4%
Septerna, Inc. logo
Septerna, Inc.SEPN
-$16.84M+41.9%
RFL
Rafael Holdings, Inc.RFL
-$6.87M-16.2%
4D Molecular Therapeutics logo
4D Molecular TherapeuticsFDMT
-$73.62M-37.3%
Denali Therapeutics Inc. logo
Denali Therapeutics Inc.DNLI
-$130.54M+3.3%

Other financials

Income statement

See full
Operating income-$29.6M-50.6%
Net income-$26.8M-62.5%
EPS (diluted)-$0.60+3.2%

Balance sheet

See full
Cash & equivalents$64.3M-23.2%
Total debt$8.4M-11.8%
Total equity$288.2M-18.1%
Total assets$305.0M-17.5%

Cash flow

See full
Operating cash flow-$21.8M-34.1%
CapEx--100%
Free cash flow-$21.8M-33.4%

Valuation

See full
Market cap$203.46M-77.0%
Enterprise value$147.55M-82.7%

Returns & leverage

See full
Return on equity-26.7%
Debt / equity0.0×
Current ratio22.6×-6.1×

Where this comes from

Calculated from Sionna Therapeutics’s reported figures.

The source filing: Sionna Therapeutics’s 10-Q, filed May 12, 2026. Open the filing →

Filed
May 12, 2026, 7:17 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001628280-26-033876

FAQ

What is Sionna Therapeutics's EBIT?
Sionna Therapeutics (SION) reported EBIT of -$29.6M in Q1 2026.
How has Sionna Therapeutics's EBIT changed year-over-year?
Sionna Therapeutics's EBIT decreased by 50.6% year-over-year, from -$19.66M to -$29.6M.
What does EBIT mean?
Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.

Ask your AI about Sionna Therapeutics's ebit.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude